Anti-Tumor Drugs Under Closer Scrutiny As China Confronts Widespread Misuse
China has introduced new rules relating to the designation and control of cancer drugs, which are being seen by some specialists as not ideal from a clinical practice perspective but positive for novel drug development.
You may also be interested in...
With the COVID-19 situation spiraling out of control in India, Brazil and other parts of the world, calls for the suspension of IP protections on coronavirus vaccines are growing louder. But the R&D based pharmaceutical industry insists a waiver is not the way forward.
Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.
Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.